| 臺大學術典藏 |
2022-09-20T06:48:35Z |
2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension
|
Huang W.-C.; Hsu C.-H.; Sung S.-H.; Ho W.-J.; Chu C.-Y.; Chang C.-P.; Chiu Y.-W.; Wu C.-H.; Chang W.-T.; Lin L.; Lin S.-L.; Cheng C.-C.; Wu Y.-J.; Wu S.-H.; Hsieh T.-Y.; Hsu H.-H.; Fu M.; Dai Z.-K.; Kuo P.-H.; HWANG, JUEY-JEN; Cheng S.-M.; TSOC pulmonary hypertension committee |
| 臺大學術典藏 |
2022-09-20T06:48:33Z |
Management of venous thromboembolisms: Part ii. the consensus for pulmonary embolism and updates
|
Wang K.-L.; Kao Y.-T.; Chang W.-T.; Chang H.-Y.; Huang W.-C.; Hsu P.-C.; Hsu C.-H.; Huang C.-L.; Hsieh L.-C.; Wang C.-Y.; Lin Y.-H.; Lin T.-H.; Chiu K.-M.; HWANG, JUEY-JEN; Chu P.-H. |
| 臺大學術典藏 |
2022-09-20T06:48:28Z |
Post-cardiac arrest care and targeted temperature management: A consensus of scientific statement from the Taiwan Society of Emergency & Critical Care Medicine, Taiwan Society of Critical Care Medicine and Taiwan Society of Emergency Medicine
|
Chiu W.-T.; Lin K.-C.; Tsai M.-S.; Hsu C.-H.; Wang C.-H.; Kuo L.-K.; Chien Y.-S.; Wu C.-H.; Lai C.-H.; Huang W.-C.; Wang C.-H.; Wang T.-L.; Hsu H.-H.; Lin J.-J.; HWANG, JUEY-JEN; Ng C.-J.; Choi W.-M.; Huang C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:59Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H.; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Chia-Chi Lin; Bu C.-F.; Yeh K.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:59Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Chia-Chi Lin; Hsu C.-H.; Chen J.; Tsai T.-C.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:09:56Z |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity
|
Chia-Chi Lin; Hsu C.-H.; Huang C.-Y.; Cheng A.-L.; Chen J.; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:09:56Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Chia-Chi Lin; Hsu C.-H.; Huang C.-Y.; Cheng A.-L.; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:09:56Z |
Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case study
|
Chia-Chi Lin; Hsu C.-H.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:09:55Z |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer
|
Chia-Chi Lin; Hsu C.-H.; Cheng J.C.; Wang H.-P.; Lee J.-M.; Yeh K.-H.; Yang C.-H.; Lin J.-T.; Cheng A.-L.; Lee Y.-C. |
| 臺大學術典藏 |
2022-09-15T01:09:55Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Chia-Chi Lin; Cheng A.-L.; Hsu C.-H.; Lu Y.-S.; Hsu C.; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:54Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Chia-Chi Lin; Hsu C.; Hsu C.-H.; Hsu W.-L.; Cheng A.-L.; Yang C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:54Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Chia-Chi Lin; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:09:54Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Chia-Chi Lin; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:09:53Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Chia-Chi Lin; Hsu C.-H.; Hour T.-C.; Cheng A.-L.; Huang C.-Y.; Huang K.-H.; Chen J.; Pu Y.-S. |
| 臺大學術典藏 |
2022-09-15T01:09:53Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Chia-Chi Lin; Yeh K.-H.; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:52Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Chia-Chi Lin; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:52Z |
Systemic therapy for metastatic urothelial carcinoma
|
Chia-Chi Lin; Hsu C.-H.; Pu Y.-S.; Vogelzang N.J. |
| 臺大學術典藏 |
2022-09-15T01:09:51Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Chia-Chi Lin; Pu Y.-S.; Hsu C.-H.; Keng H.-Y.; Cheng A.-L.; Yang C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:51Z |
Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study
|
Hsu F.-M.; Chia-Chi Lin; Lee J.-M.; Chang Y.-L.; Hsu C.-H.; Tsai Y.-C.; Lee Y.-C.; Cheng J.C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:06Z |
Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
|
Guo J.-C.; Chia-Chi Lin; Lin C.-Y.; Hsieh M.-S.; Kuo H.-Y.; Lien M.-Y.; Shao Y.-Y.; Huang T.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2022-09-15T01:09:01Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Chia-Chi Lin; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-09-15T01:08:47Z |
Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites
|
Guo J.-C.; Lin C.-Y.; Chia-Chi Lin; Huang T.-C.; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2022-09-15T01:08:43Z |
Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy
|
Huang T.-C.; Liang C.-W.; Li Y.-I.; Guo J.-C.; Chia-Chi Lin; Chen Y.-J.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-09-14T01:29:23Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; CHIEN-HUNG CHEN; Cheng A.-L. |
